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Disease, Silent Killer
Vicente Vanaclocha, Nieves Saiz-Sapena and Leyre Vanaclocha
1. Introduction
Moyamoya disease is a cerebrovascular ailment that entails a progressive 
steno-occlusive process of the terminal internal carotid artery and its main 
branches. Secondarily it induces the development of an extensive network of 
unusual reticular collateral vessels at the skull base, mainly at the lenticulostri-
ate and choroidal arteries [1–4]. These abnormal vessels create a hazy picture on 
cerebral angiogram that looks like a “puff of cigarette smoke drifting in the air” 
[5], which is the meaning of moyamoya in the Japanese language. These abnormal 
collateral vessels undergo pathological changes that lead to the appearance of 
haemorrhages [6].
Moyamoya disease leads to ischemic and haemorrhagic brain strokes and 
induces cognitive impairment [2, 7–9], partly due to the cerebrovascular insults 
[8], chronic brain hypoperfusion and white matter involvement [10]. The cognitive 
decline seems to be more severe in the haemorrhagic than in the ischemic type [11]. 
Disease progression is typical if left untreated [12].
Moyamoya disease aetiology is mostly unknown [13, 14], and without precise 
knowledge in this area, it is challenging to devise an effective treatment that 
prevents and cures this disease.
2. Disease incidence and prevalence
It is more prevalent in East Asian countries [15–17], namely Japan (10.3/100,000 
people in 2006) [5], Korea (9.1/100,000 in 2008) [18] and China (3.92/100,000 in 
2010) [19] than in the USA [20] and Europe [21].
Moyamoya incidence and prevalence have been increasing steadily over the 
years. In Japan the reported incidence rose from 0.35/100,00 in 1995 [16] to 
0.54/100,000 in 2003 [5] and 0.94/100,000 in 2006 and the prevalence from 
3.16/100,000 in 1995 [16], to 6.03/100,000 in 2003 [5] and 10.4/100,000 in 2006 
[5], with a 1.8:1 female to male ratio [22] and a 10%-15% [5, 22, 23] familial cases. 
Another important aspect is that while the affected parents presented moyamoya 
related clinical symptoms at 22-36 years of age, their siblings showed the first 
symptoms when they were 5-11 years old [24]. In the USA [25] and Europe [21], the 
incidence in 10 times smaller, and the female to male ratio 2.2:1 [21]. In 2005 in the 
USA, the incidence was 0.086 cases/100,000 inhabitants [20].
Moyamoya disease has two peaks in incidence. The first in children before 
18 years of age (maximum at 5-9 years old) and the second in adults in the 
fourth and fifth decades of life (highest rate from 35 to 45 years of age) [5, 17, 
22, 26, 27]. In 47.8% of the patients, symptoms start before ten years of age [14]. 
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In Japan, the paediatric prevalence is the highest worldwide, with 3 cases per 
100,000 children [5, 22, 28].
3. Asymptomatic moyamoya disease
It has been described as moyamoya features in the absence of any ischemic or 
haemorrhagic stroke [12]. The number of these patients has increased progressively 
over the years with improved diagnostic capacities [5, 24, 29–32] and the introduction 
of regular medical brain check-ups [12, 33]. In the Japan brain check-ups, the per-
centage of positive asymptomatic moyamoya patients was 0.07% (0.05% for males 
and 0.10% for females) with a female to male ratio of 3.3:1, mean age of 54 years [33]. 
Most of these asymptomatic patients were adults [34–37]. In children, the diagnosis 
can be unduly delayed due to their inability to communicate adequately, particularly 
at a very young ages [38].
But clinically asymptomatic patients do not mean that they have no pathological 
findings. In Japan, 20-30% of them harboured a cerebral infarction in watershed 
brain areas [24, 31] while the incidence of asymptomatic brain infarction in the 
general Japanese population in their fifth decade of life was 4.4% [39]. Additionally, 
15-44% of adult moyamoya asymptomatic patients have clinically silent microbleeds 
[40–42] in the basal ganglia, thalamus and periventricular areas [43]. In a multicenter 
study in Japan, 34.3% of asymptomatic moyamoya patients with a normal cerebral 
blood flow had reduced cerebral vascular reserve [43]. In the follow-up, 12.5% [30] to 
30% [12] of these patients suffered transitory ischemic attacks, ischemic or haemor-
rhagic stroke [12, 24, 31, 32], with a 3.2% annual stroke risk [12, 30, 31]. The female 
gender was associated with a greater risk of disease progression [31].
In Korea, the symptomatic progression in asymptomatic moyamoya patients 
was radiological in 12% and clinical in 5.3% with a reduced cerebral reserve capac-
ity in 9.3% [30]. Clinical progression has been the rule worldwide for paediatric 
asymptomatic moyamoya patients [44]. As asymptomatic moyamoya disease is not 
a stable situation [12, 45, 46] close surveillance is mandatory, notably if there is a 
reduced cerebral vascular reserve [12, 30], ivy sign on MRI flair imaging [47, 48] 
or smoking habit [12]. The ivy sign is associated with an impaired cerebrovascular 
hemodynamic status [47]. It has been reported in 31.3% of asymptomatic moyam-
oya patients [47] that rises to 66% in those that already have ischemic stroke-related 
symptoms [48–50].
Moreover, these patients are not entirely asymptomatic but suffer from a steady 
cognitive decline in intelligence, spatial imagination, working memory, working 
memory-backwards digit span, computational ability, complex subtraction, complex 
arithmetic and word short-term memory [8, 51], particularly in children [45, 52, 53]. 
This cognitive decay precedes the onset of clinical symptoms due to brain infarction, 
or haemorrhage [8] and inevitable worsens when these cerebrovascular insults hap-
pen [51, 54]. Additionally, asymptomatic moyamoya patients can suffer from isch-
emic or haemorrhagic strokes [31]. Another critical aspect is that 20% of moyamoya 
children who undergo ischemic strokes are handicapped to undergo an independent 
social life [45, 53, 55].
Some have recommended performing surgical revascularization on asymptom-
atic moyamoya patients, particularly children, to prevent this unpleasant progres-
sive neurological and cognitive deterioration [30, 44, 54]. Some have suggested 
undertaking surgical treatment if the ivy sign is seen in MRI flair imaging [47]. In 
any case, symptomatic progression in previously asymptomatic patients should be 
addressed with aggressive surgical revascularization in adults and children [30] as it 
halts disease progression [31].
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4. Treatment modalities
Medical treatment with antithrombotic drugs (aspirin [56], cilostazol [57], 
clopidogrel [58, 59], low molecular-weight heparin, argatroban) [60] or calcium 
channel blockers [61] is used for mild asymptomatic cases, although their effec-
tiveness has never been proven convincingly [15, 62]. Cilostazol is preferred over 
aspirin and clopidogrel because of its lower hemorrhagic risk [60], and clopidogrel 
recommended when aspirin is not tolerated [60]. These antithrombotic agents are 
advised for the ischemic-type moyamoya disease [15]. In any case, they are not very 
useful [63] as some researchers have reported an almost 3-fold chance of future 
neurological deterioration in the patients treated conservatively compared to those 
treated surgically [54, 64].
Direct, indirect or combined revascularization provides much better long-term 
results than conservative treatment, minimising the risk of ischemic and haemor-
rhagic strokes [54, 65, 66]. Early surgical intervention, particularly in paediatric 
patients, reduces cerebrovascular events and should be considered in asymptomatic 
children [44, 67]. Specific hospital perioperative morbidity and mortality have 
to be considered when recommending surgical treatment to these patients [12]. 
Thus, surgical treatment should be advised a soon as there is any sign of clinical or 
subclinical deterioration.
5. Conclusions
Moyamoya disease is more prevalent than previously thought because many 
patients go undiagnosed. Once diagnosed, asymptomatic patients may already 
harbour a cognitive decline long before cerebrovascular events take place. The only 
effective treatment is surgical revascularization, which should be undertaken as 
soon as any clinical deterioration sign occurs. Many posit that preventive surgical 
treatment should be recommended to asymptomatic patients, particularly in the 
paediatric age group.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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